Overview

HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study

Status:
Not yet recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

The use of corticosteroids in patients with severe community pneumonia, bacterial infection which kills lots of patients around the world, reduces the mortality of this infection. However, there are no studies with this type of drug regarding hospital-acquired pneumonia. This will be the first multicenter randomized, double-blind, controlled trial to test hydrocortisone plus standard therapy in critical care patients with nosocomial pneumonia. This intervention is inexpensive and may improve the outcome of those patients, besides having an acceptable side effects profile.

Phase:

N/A

Details

Lead Sponsor:

Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo

Collaborators:

Fundação Faculdade Regional de Medicina de São José do Rio Preto
Hospital de Câncer de Barretos
Hospital Samaritano Paulista
Instituto do Cancer do Estado de São Paulo
University of Sao Paulo

Treatments:

Hydrocortisone
Hydrocortisone hemisuccinate